Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-089 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | - |
| 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ABT-089 | DRUG | Subjects will take 2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD, 40 mg BID for 4-6 weeks |
| Placebo | DRUG | Subjects will take placebo QD, BID for 4-6 weeks |
Inclusion Criteria: * Meet criteria for attention deficit hyperactivity disorder * Have voluntarily signed an informed consent form * Are between 18 and 60 years of age * Will use contraceptive methods during the study * Women must not be pregnant or breast-feeding * Must be in generally good healt...
ABT-089 is an investigational small molecule being studied for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults. It is in Phase 2 clinical development and has not been approved by the FDA. One clinical trial has been completed to evaluate its safety and efficacy in this patient population.
ABT-089 is being developed by Abbott Laboratories, a company traded on the New York Stock Exchange under the ticker symbol ABT. The drug is an investigational small molecule in Phase 2 clinical development for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults.
ABT-089 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 2 clinical trial studying the drug in adults with Attention-Deficit/Hyperactivity Disorder (ADHD) has been completed.
ABT-089 has one completed clinical trial, identified as NCT00391729. This was a Phase 2, dose-ranging, cross-over study evaluating the safety and efficacy of ABT-089 in adults with Attention-Deficit/Hyperactivity Disorder (ADHD). The trial enrolled 221 participants in the United States and was randomized, double-blind, and placebo-controlled.
No, ABT-089 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults. One clinical trial has been completed, but the drug has not yet received regulatory approval.